Table 4. Relationships between Clinicopathological Characteristics and the Combination of Preoperative NLR and PLR in Papillary Thyroid Cancer Patients.
| Characteristic | Score 0 | Score 1 | Score 2 | P value |
|---|---|---|---|---|
| No. in quartile | 334 | 517 | 215 | |
| NLR | 1.23 (0.25-1.87) | 1.57 (0.57-5.09) | 2.50 (1.88-10.20) | |
| PLR | 103.95 (13.32-143.82) | 125.43 (47.99-294.70) | 181.01 (144.07-407.81) | |
| Age, yr | 51.58±11.36 | 50.09±10.95 | 48.33±11.47a | 0.004 |
| BMI, kg/m2 | 24.20±11.91 | 23.34±3.17 | 23.28±3.07 | 0.178 |
| Tumor size, cm | 0.85±0.57 | 0.86±0.59 | 0.88±0.60 | 0.876 |
| TSH, mIU/L | 1.32 (0.79-2.33) | 1.43 (0.91-2.24) | 1.29 (0.86-2.12) | 0.507 |
| T stage 3/4, % | 43 (12.9) | 52 (10.1) | 27 (12.6) | 0.383 |
| LNM, % | 214 (64.1) | 296 (57.3) | 124 (57.7) | 0.118 |
| Lateral LNM, % | 19 (5.7) | 34 (6.6) | 12 (5.6) | 0.817 |
| Multifocality, % | 107 (32.0) | 153 (29.6) | 60 (27.9) | 0.563 |
| ETE, % | 126 (37.7) | 203 (39.3) | 83 (38.6) | 0.903 |
| LVI, % | 65/218 (29.8) | 82/343 (23.9) | 44/154 (28.6) | 0.256 |
| BRAF V600E mutation, % | 191/312 (61.2) | 305/488 (62.5) | 124/203 (61.1) | 0.909 |
Values are expressed as median (interquartile range), mean±SD, or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.
NLR, neutrophil-to-lymphocyte count ratio; PLR, platelet-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.
aThe differences were significant only between the score 0 and the score 2.